Kaiku Health secures EUR 4.4 million funding
Finnish digital health company Kaiku Health will use the significant funding towards international expansion and to further develop its digital therapeutics pipeline.
The funding round was led by Debiopharm Innovation Fund SA and Tesi, with participation from Prodeko Ventures and return investors Reaktor Ventures, Metsola Ventures, and Athensmed.
Kaiku Health‘s intelligent patient monitoring software helps healthcare providers evaluate the effectiveness of therapies, and detect and treat health problems early on. It’s already used in routine care in more than 30 clinics in Switzerland, Germany, Italy, Sweden, and Finland, and has been tried out by 64 000 patients.
“We have seen the significant positive impact our patient monitoring platform can have on people’s health,” says Lauri Sippola, co-founder and CEO of Kaiku Health. “This funding allows us to provide our platform to a growing number of healthcare providers and patients internationally. It is important that our investors also bring an extraordinary understanding of healthcare, life sciences and digitalization.”
Kaiku Health will also use the funding to conduct several clinical trials together with its partners, in order to validate and further develop its digital therapeutics offering.
Looking for more good news? Subscribe to our newsletter